Arthrex, Inc.

Based in the US, Arthrex, Inc. develops innovative orthopedic surgical equipment and implants, aiming to enhance surgical outcomes for minimally invasive procedures worldwide. Founded in 1981, Arthrex, Inc. specializes in orthopedic surgical solutions.

The company is headquartered in Naples, Florida, US. In January 2020, Arthrex raised EUR 1. 5 million through a Seed funding round led by Invivo Capital Partners, bringing its total amount raised to EUR 1. 5 million.

The firm has not undergone any notable pivots in its business strategy or operations. Arthrex specializes in developing innovative orthopedic surgical equipment and implants aimed at enhancing surgical outcomes for minimally invasive procedures. Their core product offerings include the iBalance® UKA system for partial knee replacements, which improves surgical efficiency and accuracy, and the TensionTight™ button used for knotless biceps tenodesis. Additionally, the company produces the OsteoAuger™ Bone Graft Harvesting System, enabling surgeons to efficiently recover autogenous bone, and the ACL TightRope II implant, known for its adjustable-loop mechanism that enhances graft tensioning.

Arthrex's products cater primarily to orthopedic surgeons and healthcare professionals globally, with significant markets in North America, Europe, and Asia. The company emphasizes clinical innovations that support orthopedic procedures, thereby addressing the challenges faced by surgeons in various specialties, including sports medicine and joint reconstruction. Arthrex generates revenue through direct sales of its surgical products and instruments to healthcare providers, surgical centers, and hospitals across multiple regions. The company employs a B2B transaction structure, where orthopedic surgeons and medical institutions purchase products directly, often facilitated through partnerships or agreements that include training and support.

Flagship products such as the iBalance® UKA system and the ACL TightRope II implant are key drivers in its sales strategy, contributing to Arthrex's growing portfolio of advanced surgical solutions. Pricing structures for these products are aligned with the value they provide in enhancing surgical procedures, with an emphasis on long-term partnerships with healthcare professionals to improve patient outcomes. The ongoing education and training provided by Arthrex further solidify client relationships and support the effective use of their innovative tools and techniques. In January 2020, Arthrex, Inc.

raised EUR 1. 5 million in Seed funding from Invivo Capital Partners to support its growth initiatives. The company is expected to focus on launching new surgical products aimed at improving surgical outcomes. Furthermore, Arthrex plans to expand into new geographic markets, with specific targets in Asia and Europe by 2023.

The funding will be utilized to enhance product development and to establish a stronger presence in these regions.